EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the p90RSK/MDM2/p53 Pathway Is Effective in Blocking Tumors with Oncogenic Up-Regulation of the MAPK Pathway Such as Melanoma and Lung Cancer

Immacolata Maietta iD, Eleonora Viscusi, Stefano Laudati iD, Giuseppe Iannaci, Antonio D'Antonio, Rosa Marina Melillo iD, Maria Letizia Motti iD, Valentina De Falco iD

Cells · 2024

DOI: 10.3390/cells13181546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Immacolata Maietta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Endocrinology and Experimental Oncology (IEOS), National Research Council (CNR), Via S. Pansini 5, 80131 Naples, Italy. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Tumor Suppressor Protein p53, Melanoma, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: POR FESR 2014-2020 Technology Platform -Fight Against Oncological Pathologies-, SIRCI Grant, POR FESR 2014–2020 Technology Platform—Fight Against Oncological Pathologies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In most human tumors, the MAPK pathway is constitutively activated. Since p90RSK is downstream of MAPK, it is often hyperactive and capable of phosphorylating oncogenic substrates. We have previously shown that p90RSK phosphorylates MDM2 at S166, promoting p53 degradation in follicular thyroid carcinomas. Thus, the inhibition of p90RSK restores p53 expression, which in turn inhibits cell proliferation and promotes apoptosis. In the present study, we demonstrated that the p90RSK/MDM2/p53 pathway proved to be an excellent target in the therapy of tumors with MAPK hyperactivation. For this purpose, we selected p53wt melanoma, lung and medullary thyroid carcinoma cell lines with high activation of p90RSK. In these cell lines, we demonstrated that the p90RSK/MDM2/p53 pathway is implicated in the regulation of the cell cycle and apoptosis through p53-dependent transcriptional control of p21 and Bcl-2. Furthermore, with an immunohistochemical evaluation of primary melanomas and lung tumors, which exhibit highly activated p90RSK compared to corresponding normal tissue, we demonstrated that MDM2 stabilization was associated with p90RSK phosphorylation. The results indicate that p90RSK is able to control the proliferative rate and induction of apoptosis through the regulation of p53wt levels by stabilizing MDM2 in selected tumors with constitutively activated MAPKs, making p90RSK a new attractive target for anticancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53MelanomaLung NeoplasmsMAP Kinase Signaling SystemRibosomal Protein S6 Kinases, 90-kDaApoptosisHumansCell Line, TumorUp-RegulationCell ProliferationPhosphorylationCyclin-Dependent Kinase Inhibitor p21

Stichwörter der Autor:innen

MDM2apoptosiscancercancer drug resistancecell proliferationp53p90RSKtargeted therapytumorigenesis

Substanzen

Proto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53Ribosomal Protein S6 Kinases, 90-kDaMDM2 protein, humanCyclin-Dependent Kinase Inhibitor p21

Autor:innen und Institutionen

  • Institute of Endocrinology and Experimental Oncology (IEOS), National Research Council (CNR), Via S. Pansini 5, 80131 Naples, Italy.
  • U.O.C. Anatomia Patologica, P.O. Pellegrini ASL NA1 Centro, 80134 Naples, Italy.
  • U.O.C. Anatomia Patologica, Ospedale del Mare ASL NA1 Centro, 80147 Naples, Italy.
  • Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
  • Department of Medical, Movement and Wellbeing Sciences, University of Naples Parthenope, 80133 Naples, Italy.

ORCID-Profile: Immacolata Maietta, Stefano Laudati, Rosa Marina Melillo, Maria Letizia Motti, Valentina De Falco

Förderung

  • POR FESR 2014-2020 Technology Platform -Fight Against Oncological Pathologies-
  • SIRCI Grant
  • POR FESR 2014–2020 Technology Platform—Fight Against Oncological Pathologies
  • SIRCI

Zitieren

APA

Maietta, I., Viscusi, E., Laudati, S., Iannaci, G., D'Antonio, A., Melillo, R. M., Motti, M. L., & De Falco, V. (2024). Targeting the p90RSK/MDM2/p53 Pathway Is Effective in Blocking Tumors with Oncogenic Up-Regulation of the MAPK Pathway Such as Melanoma and Lung Cancer. Cells. https://doi.org/10.3390/cells13181546

Vancouver

Maietta I, Viscusi E, Laudati S, Iannaci G, D'Antonio A, Melillo RM, et al. Targeting the p90RSK/MDM2/p53 Pathway Is Effective in Blocking Tumors with Oncogenic Up-Regulation of the MAPK Pathway Such as Melanoma and Lung Cancer. Cells. 2024. doi:10.3390/cells13181546

BibTeX
@article{Maietta2024,
  author = {Maietta, Immacolata and Viscusi, Eleonora and Laudati, Stefano and Iannaci, Giuseppe and D'Antonio, Antonio and Melillo, Rosa Marina and Motti, Maria Letizia and De Falco, Valentina},
  title = {Targeting the p90RSK/MDM2/p53 Pathway Is Effective in Blocking Tumors with Oncogenic Up-Regulation of the MAPK Pathway Such as Melanoma and Lung Cancer},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13181546}
}
Kostenlos starten →